Updating Appendix definition

Updating Appendix. “A” - Job Classifications Appendix "A" will be updated as appropriate by Compensation Services to reflect completed evaluations.
Sample 1Sample 2
Updating Appendix. “A” - Job Classifications Appendix "A" will be updated annually by Compensation Services to reflect completed evaluations. A copy of the updated Appendix “A” will be provided to the Union electronically on an annual basis.
Sample 1Sample 2Sample 3

Examples of Updating Appendix in a sentence

  • Updating Appendix A does not require either party to re-sign this ISA.

  • Updating Appendix B does not require the re-signing of this ISA by either party.

  • So the execution of a professional and global qualification demand analysis within a job rotation project can be assumed as an important success-critical variable for the implementation for example.

  • Updating Appendix C-5: Home and Community-Based Settings in response to guidance received from CMS in recent renewals about how to complete this section.

  • Miscellaneous: Updating Appendix B with the specifics of the citation programs that have issued since the Commission enacted Resolution ALJ-299, or which were inadvertently omitted.

  • Updating Appendix I to reflect that the A&D waiver will also be operated in conjunction with a 1915(b) waiver for Idaho Medicaid Plus (in addition to the existing 1915(a)/(c) authority for MMCP).

  • This should include a decision on whether the differentiation between a very cost-effective and cost-effective intervention is maintained.The proposed methodology that emerged from the meeting is included in Annex 1.Annex 1: Proposed Method for Updating Appendix 3 of the Global NCD Action Plan1.

  • Establishing double striping as the universal standard.3. Updating Appendix A to make it the Specification Document- redesign to address construction specifications (e.g.; striping width, how stall width is measured, drive aisle measurement, etc.)4.

  • Figures taken from Core Document HOU43 Summary Tables Updating Appendix 2 Table 2 (1st August 2007 version).

  • Updating Appendix B to remove certain positions from the list of safety sensitive positions.

Related to Updating Appendix

  • Development Schedule shall have the meaning set forth in Section 1.1.

  • Additional Indication means any indication other than the Initial Indication.

  • Additional SDU Study means a deliverability study that a Developer may elect to pursue as that term is defined in OATT Section 25 (OATT Attachment S). For purposes of Section 23.4.5 of this Attachment H, “Affiliated Entity” shall mean, with respect to a person or Entity:

  • Development Application means the development application identified in Item 5 of Schedule 1 and includes all plans, reports models, photomontages, material boards (as amended supplemented) submitted to the consent authority before the determination of that Development Application.

  • Planning Application means the application for [outline/full] planning permission dated [ ] bearing the Council’s reference number [ ];

  • Development Plan has the meaning set forth in Section 3.2.

  • Marketing Approval Application or “MAA” means a New Drug Application (or its equivalent), as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any country.

  • Additional Product means any Product identified as such in the Product Terms and chosen by Enrolled Affiliate under this Enrollment.

  • Initial application means the Application first provided to MFA on or before an Application Deadline to request an allocation of Tax Credits.

  • Initial Indication means the treatment of Netherton Syndrome in humans in the Territory.

  • Drug Approval Application means, with respect to a Licensed Product in the Territory, an application for Regulatory Approval for such product in a country in the Territory. For purposes of clarity, Drug Approval Application shall include, without limitation, (a) an NDA or BLA (for U.S.) or MAA (for Europe); (b) a counterpart of an NDA, BLA or MAA in any country or region in the Territory; and (c) all supplements (including supplemental applications such as sNDAs) and amendments to the foregoing.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • extended producer responsibility ’ (EPR) means responsibility of any producer of packaging products such as plastic, tin, glass, wrappers and corrugated boxes, etc., for environmentally sound management, till end-of-life of the packaging products ;

  • Account Opening Application Form means the application form/questionnaire completed by the Client in order to apply for the Company’s Services under this Agreement and a Client Account, via which form/questionnaire the Company will obtain amongst other things information for the Client’s identification and due diligence, his categorization and appropriateness or suitability (as applicable) in accordance with the Applicable Regulations.

  • Regulatory Approval Application means an application to seek regular or expedited Regulatory Approval of the Licensed Product for sale or marketing in any country(ies) or Region(s) in the Territory, as defined in the applicable Laws and filed with the Regulatory Authority of such country(ies) or Region(s).

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Marketing Authorization Application or “MAA” means an application to the appropriate Regulatory Authority for approval to sell the Product (but excluding Pricing Approval) in any particular country or regulatory jurisdiction.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • NDA means a New Drug Application, as defined in the regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof.

  • Pricing Approval means such mandatory governmental approval, agreement, determination or decision establishing prices for the Product that can be charged and/or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the price and/or reimbursement of pharmaceutical products.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • New Drug Application means a New Drug Application filed with the FDA in accordance with Applicable Law.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Product Schedule means PTC’s standard order form entitled “PTC Product Schedule” (including all schedules, attachments and other document(s) specifically referenced therein) or such alternative order form as may be submitted by Customer and accepted by PTC, in each case that specifies (i) the Licensed Products and/or Services ordered; and (ii) for Licensed Products, the installation address (including the Designated Country) and the Licence Term.